{"transactions":[{"id":778879,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-14T20:27:29.000Z","date":"2026-05-13","kind":"grant","planned":false,"acquired":true,"shares":5550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":5550,"derivative":{"exercise_price":30.14,"exercise_date":"2027-05-13","expiration_date":"2036-05-12","underlying":"Common Stock","underlying_shares":5550},"source":{"system":"sec-edgar","filing":"0001193125-26-224145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000119312526224145/ownership.xml","form_type":"4"}},{"id":1147238,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-15T21:26:22.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":6.5,"exercise_date":"2026-05-14","expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-25-000612","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000159396825000612/primary_01.xml","form_type":"4"}},{"id":1488266,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-07T00:22:45.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":11,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-24-000828","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000159396824000828/primary_01.xml","form_type":"4"}},{"id":1884401,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-05-19T20:11:53.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":0.56,"exercise_date":"2023-06-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-23-000839","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000159396823000839/primary_01.xml","form_type":"4"}},{"id":2237582,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-09T21:55:56.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director."}],"balance_after":20000,"derivative":{"exercise_price":2.79,"exercise_date":"2023-06-07","expiration_date":"2032-06-07","underlying":"Surrozen, Inc. Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-22-001113","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000159396822001113/primary_01.xml","form_type":"4"}},{"id":3021661,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021660,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021659,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":44034,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":11.3549,"expiration_date":"2028-08-23","underlying":"Common Stock","underlying_shares":44034},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021658,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":34677,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":7.2671,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":34677},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021657,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":13210,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.9961,"expiration_date":"2025-07-20","underlying":"Common Stock","underlying_shares":13210},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021656,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":29723,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.7236,"expiration_date":"2024-12-25","underlying":"Common Stock","underlying_shares":29723},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021655,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":24769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":3.1794,"expiration_date":"2024-06-26","underlying":"Common Stock","underlying_shares":24769},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021654,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":56982,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-12-11","underlying":"Common Stock","underlying_shares":56982},"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021653,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":3302,"price":100,"value":330200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Christopher Chai, as a fiduciary for his children, of which the Reporting Person may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3021652,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-28T21:11:14.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":3799,"price":100,"value":379900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 260 shares acquired under the Employment Stock Purchase Plan on September 25, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120052224/doc4.xml","form_type":"4"}},{"id":3050967,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-21T00:01:46.000Z","date":"2020-08-18","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":56982,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-12-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-20-047832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120047832/doc4.xml","form_type":"4"}},{"id":3050966,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-21T00:01:46.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":7500,"price":99.3653,"value":745239.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $99.28 to $99.50 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":3539,"source":{"system":"sec-edgar","filing":"0001209191-20-047832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120047832/doc4.xml","form_type":"4"}},{"id":3050965,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-21T00:01:46.000Z","date":"2020-08-18","kind":"exercise","acquired":true,"shares":7500,"price":2.9977,"value":22482.75,"ownership":{"direct":true},"balance_after":11039,"source":{"system":"sec-edgar","filing":"0001209191-20-047832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120047832/doc4.xml","form_type":"4"}},{"id":3139001,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-22T00:01:31.000Z","date":"2020-05-19","kind":"exercise","acquired":false,"shares":5675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":64482,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-12-11","underlying":"Common Stock","underlying_shares":5675},"source":{"system":"sec-edgar","filing":"0001209191-20-031531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120031531/doc4.xml","form_type":"4"}},{"id":3139000,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-22T00:01:31.000Z","date":"2020-05-19","kind":"sale","acquired":false,"shares":7500,"price":65.1024,"value":488268.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $64.90 to $65.71 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":3539,"source":{"system":"sec-edgar","filing":"0001209191-20-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120031531/doc4.xml","form_type":"4"}},{"id":3138999,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-22T00:01:31.000Z","date":"2020-05-19","kind":"exercise","acquired":true,"shares":5675,"price":2.9977,"value":17011.9475,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 598 shares acquired under the Employment Stock Purchase Plan on May 15, 2020."}],"balance_after":11039,"source":{"system":"sec-edgar","filing":"0001209191-20-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120031531/doc4.xml","form_type":"4"}},{"id":3224530,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-05T22:26:01.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":55000,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-016690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120016690/doc4.xml","form_type":"4"}},{"id":3259241,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":70157,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-12-11","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259240,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":76,"price":68.5218,"value":5207.6568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $68.48 to $68.66 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":4766,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259239,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":2240,"price":68.1302,"value":152611.648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $67.46 to $68.415 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":4842,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259238,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":605,"price":67.078,"value":40582.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $66.45 to $67.44 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":7082,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259237,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1350,"price":65.9415,"value":89021.025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $65.41 to $66.33 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":7687,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259236,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":545,"price":64.9075,"value":35374.5875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $64.30 to $65.19 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":9037,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259235,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":2684,"price":63.8558,"value":171388.9672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $63.14 to $63.88 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":9582,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3259234,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-20T22:02:49.000Z","date":"2020-02-18","kind":"exercise","acquired":true,"shares":2500,"price":2.9977,"value":7494.25,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,991 shares and 950 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively."}],"balance_after":12266,"source":{"system":"sec-edgar","filing":"0001209191-20-011163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919120011163/doc4.xml","form_type":"4"}},{"id":3603999,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":47300,"kind":"person","name":"CHAI CHRISTOPHER Y","position":1,"cik":"0001413823","reported_name":"CHAI CHRISTOPHER Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-08T22:33:35.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 1, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-018221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413823/000120919119018221/doc4.xml","form_type":"4"}}]}